BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 15687339)

  • 1. Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas.
    Porra V; Ferraro-Peyret C; Durand C; Selmi-Ruby S; Giroud H; Berger-Dutrieux N; Decaussin M; Peix JL; Bournaud C; Orgiazzi J; Borson-Chazot F; Dante R; Rousset B
    J Clin Endocrinol Metab; 2005 May; 90(5):3028-35. PubMed ID: 15687339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer.
    Hu S; Liu D; Tufano RP; Carson KA; Rosenbaum E; Cohen Y; Holt EH; Kiseljak-Vassiliades K; Rhoden KJ; Tolaney S; Condouris S; Tallini G; Westra WH; Umbricht CB; Zeiger MA; Califano JA; Vasko V; Xing M
    Int J Cancer; 2006 Nov; 119(10):2322-9. PubMed ID: 16858683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating cell-free DNA, SLC5A8 and SLC26A4 hypermethylation, BRAF(V600E): A non-invasive tool panel for early detection of thyroid cancer.
    Zane M; Agostini M; Enzo MV; Casal Ide E; Del Bianco P; Torresan F; Merante Boschin I; Pennelli G; Saccani A; Rubello D; Nitti D; Pelizzo MR
    Biomed Pharmacother; 2013 Oct; 67(8):723-30. PubMed ID: 23931930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypermethylated RASSF1 and SLC5A8 promoters alongside BRAF
    Khatami F; Larijani B; Heshmat R; Nasiri S; Haddadi-Aghdam M; Teimoori-Toolabi L; Tavangar SM
    J Cell Physiol; 2020 Oct; 235(10):6954-6968. PubMed ID: 32017063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
    Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA
    Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [BRAF gene mutation in thyroid cancer].
    Kopczyńska E; Junik R; Tyrakowski T
    Pol Merkur Lekarski; 2006 Feb; 20(116):210-3. PubMed ID: 16708643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular characteristics of papillary thyroid carcinomas without BRAF mutation or RET/PTC rearrangement: relationship with clinico-pathological features.
    Durand S; Ferraro-Peyret C; Joufre M; Chave A; Borson-Chazot F; Selmi-Ruby S; Rousset B
    Endocr Relat Cancer; 2009 Jun; 16(2):467-81. PubMed ID: 19208736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
    Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
    Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Molecular analysis of structural abnormalities in papillary thyroid carcinoma gene].
    Vasil'ev EV; Rumiantsev PO; Saenko VA; Il'in AA; Poliakova EIu; Nemtsova MV; Zaletaev DV
    Mol Biol (Mosk); 2004; 38(4):642-53. PubMed ID: 15456136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism.
    Durante C; Puxeddu E; Ferretti E; Morisi R; Moretti S; Bruno R; Barbi F; Avenia N; Scipioni A; Verrienti A; Tosi E; Cavaliere A; Gulino A; Filetti S; Russo D
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2840-3. PubMed ID: 17488796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA methylation of MAPK signal-inhibiting genes in papillary thyroid carcinoma.
    Lee EK; Chung KW; Yang SK; Park MJ; Min HS; Kim SW; Kang HS
    Anticancer Res; 2013 Nov; 33(11):4833-9. PubMed ID: 24222120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene methylation in thyroid tumorigenesis.
    Xing M
    Endocrinology; 2007 Mar; 148(3):948-53. PubMed ID: 16946009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA).
    Sapio MR; Posca D; Troncone G; Pettinato G; Palombini L; Rossi G; Fenzi G; Vitale M
    Eur J Endocrinol; 2006 Feb; 154(2):341-8. PubMed ID: 16452550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silencing of the candidate tumor suppressor gene solute carrier family 5 member 8 (SLC5A8) in human pancreatic cancer.
    Park JY; Helm JF; Zheng W; Ly QP; Hodul PJ; Centeno BA; Malafa MP
    Pancreas; 2008 May; 36(4):e32-9. PubMed ID: 18437076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas.
    Puxeddu E; Moretti S; Elisei R; Romei C; Pascucci R; Martinelli M; Marino C; Avenia N; Rossi ED; Fadda G; Cavaliere A; Ribacchi R; Falorni A; Pontecorvi A; Pacini F; Pinchera A; Santeusanio F
    J Clin Endocrinol Metab; 2004 May; 89(5):2414-20. PubMed ID: 15126572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma.
    Bastos AU; Oler G; Nozima BH; Moysés RA; Cerutti JM
    Eur J Endocrinol; 2015 Oct; 173(4):525-40. PubMed ID: 26338373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
    Liu D; Hu S; Hou P; Jiang D; Condouris S; Xing M
    Clin Cancer Res; 2007 Feb; 13(4):1341-9. PubMed ID: 17317846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF mutation and RASSF1A expression in thyroid carcinoma of southern Italy.
    Santoro A; Pannone G; Carosi MA; Francesconi A; Pescarmona E; Russo GM; Feola A; Losito S; Franco R; Nappi L; Aquino G; De Rosa G; Di Domenico M; Bufo P
    J Cell Biochem; 2013 May; 114(5):1174-82. PubMed ID: 23192464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detectable BRAF mutation in serum DNA samples from patients with papillary thyroid carcinomas.
    Chuang TC; Chuang AY; Poeta L; Koch WM; Califano JA; Tufano RP
    Head Neck; 2010 Feb; 32(2):229-34. PubMed ID: 19626635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.